The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for Aerin Medical sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
Aerin Medical develops a non-invasive medical device that treats nasal obstruction and breathing disorders. The company develops VIVAER, an advanced treatment platform that treats nasal congestion and remodel nasal soft tissues utilizing low-power radio frequency energy. Its treatment styluses perform the procedures delivering energy to the target tissue surface even without allowing incisions or tissue penetration. Aerin performs treatment by maintaining the temperature below the tissue ablation range controlling the temperature exposure to the targeted tissue. The treatment uses local anesthetic allowing the patient to perform their activity normally without any nasal blockade. It has operational presence in Singapore. Aerin is headquartered in California, the US. Key subsidiaries of Aerin Medical include Aerin Medical Singapore.
The key metrics of Aerin Medical related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:
As Aerin Medical is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as Aerin Medical.
For a detailed understanding of the performance of Aerin Medical, buy the report here.